We provided an update on the potential
timelines for the
#COVID19
#vaccine candidate BNT162b2. We will seek approval only if the
data provides a clear picture in three key areas: safety, efficacy,
manufacturing quality. Read more in @WSJ by @bopanc.
https://t.co/62njuhX3lu